The application of the first immunizer against Covid-19 developed with totally national technology and inputs and financed by Brazilian institutions, begins this Friday (25) at the Federal University of Minas Gerais (UFMG).
On Thursday (17), registration was opened for people interested in being volunteers in phases 1 and 2 of the SpiN-Tec MCTI UFMG clinical trials.
Regarding phase 1, which will bring together 72 volunteers, the criteria to participate in the recruitment are to be between 18 and 85 years old, to be healthy, not to have had Covid-19, to have received the two initial doses of the Coronavac vaccine and a booster dose from Pfizer (at least nine months ago), residing in Belo Horizonte during the 12 months of the study and, in the case of women, not being pregnant or breastfeeding.
For phase 2, which will have 360 volunteers, the criteria are to be between 18 and 85 years old, to be healthy, to have received the two initial doses of the Coronavac or AstraZeneca vaccine and one or two booster doses of Pfizer or AstraZeneca, to reside in Belo Horizonte during the 12 months of study and, for women, not being pregnant or breastfeeding. The fact that you have already contracted Covid-19 does not prevent you from qualifying for the second phase of the tests.
Interested parties can do internet registration🇧🇷 Once enrolled, they will undergo screening for the selection of volunteers and will be submitted to clinical and laboratory evaluations, conducted by CTVacinas and by the Clinical Vaccine Research Unit (UPqVac), located at the Faculty of Medicine of UFMG.
Development
In preclinical tests, the vaccine did not generate adverse side effects and demonstrated the ability to produce antibodies. The tests also proved that the dose is effective against different variants of the virus, showing that there was protection for both cases of severe Covid-19 and in moderate cases.
On average, a vaccine takes 20 to 30 years to develop, but the pandemic has shortened that process. The development of SpiN-TEC has been very fast, as studies started in November 2020.
SpiN-TEC could be the first human vaccine fully developed in Brazil. For the university, this achievement leaves a legacy for the development of vaccines for other diseases.
The study is funded by UFMG, the Ministry of Science, Technology and Innovation (MCTI), Oswaldo Cruz Foundation (Fiocruz) and Belo Horizonte City Hall. The prediction is that the dose will be applied to the population from the year 2025.
This Friday (25), the Dean of UFMG, Sandra Regina Goulart Almeida, the Minister of Science, Technology and Innovation, Paulo Cesar Rezende de Carvalho Alvim, and the Secretary of Research and Scientific Training of the MCTI, Marcelo Morales, in addition to the team from the Center for Vaccine Technologies at UFMG (CTVacinas), which conducts studies on the immunizer, and the group responsible for clinical trials at the Clinical Research Unit in Vaccines (UPqVac) at UFMG.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
